Practice
Featured experience
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Azul $800 million secured notes offering
The senior secured notes are due 2028
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
NBCUniversal partnership with MultiChoice to relaunch Showmax using Peacock
We are advising NBCUniversal on the transaction to relaunch MultiChoice’s Showmax service using the Peacock platform
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S…
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
InVue sale to ASSA ABLOY
We advised InVue on the transaction
Ferrero Group acquisition of Power Crunch
We are advising Ferrero on the transaction
Arcos Dorados renewal of long-term master franchise agreement with McDonald’s
We advised Arcos Dorados on the transaction
Rokt $300 million merger with mParticle
We are advising Rokt on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition